Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. (Q51816015)
Jump to navigation
Jump to search
scientific article published on 7 August 2009
Language | Label | Description | Also known as |
---|---|---|---|
English | Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. |
scientific article published on 7 August 2009 |
Statements
Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. (English)
1 reference
John R Zalcberg
1 reference
Nicole Mittmann
1 reference
Heather-Jane Au
1 reference
Dongsheng Tu
1 reference
Christopher J O'Callaghan
1 reference
Pierre K Isogai
1 reference
Christos S Karapetis
1 reference
William K Evans
1 reference
Malcolm J Moore
1 reference
Jehan Siddiqui
1 reference
Brian Findlay
1 reference
Bruce Colwell
1 reference
John Simes
1 reference
Niall C Tebbutt
1 reference
Derek J Jonker
1 reference
Working Group on Economic Analysis of National Cancer Institute of Canada Clinical Trials Group
1 reference
Australasian Gastrointestinal Interest Group
1 reference
7 August 2009
1 reference
101
1 reference
17
1 reference
1182-1192
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference